The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Save dough on the good-good without breaking a sweat. The post Why you should shop…
Quantity vs. Frequency - One of the most significant distinctions between medical and recreational cannabis…
At least 10 states and Amsterdam have new stores for you. The post Grand Openings:…
Welcome all Stargazers! November promises a month of celestial buoyancy even as the days and…
According to fresh data from the US National Institute on Drug Abuse, young women have…
Many states have enacted strict privacy laws that prevent dispensaries from sharing customer data without…